Erstbeschreibung ALK-positives NSCLC bei herztransplantiertem Patienten

Zusammenfassung

Immunsupprimierte Patienten stellen eine besondere Herausforderung in der thoraxonkologischen Therapie dar. Infektiöse Komplikationen unter Chemotherapie einerseits sowie fehlende Wirksamkeit der onkologischen Therapie unter Immuntherapie anderseits können die Therapieauswahl erschweren. ALK-Translokationen sind seltene Treibermutationen bei nicht-kleinzelligen Lungenkarzinomen. In der Literatur ist die Behandlung ALK-positiver transplantierter Patienten bislang nicht beschrieben.

Abstract

Thoracooncological treatment under preexisting immunosuppression as in transplant patients is challenging. On the one hand, chemotherapy might potentiate infectious complications. On the other hand, checkpoint inhibitors are not effective in immunosuppressed patients. There are no reports about treatment of driver mutation among transplant patients. ALK translocation is a rare driver mutation in non-small cell lung cancer. This is a case report about treatment of a heart transplanted patient with ALK-positive non-small cell lung cancer.

Schlüsselwörter

Lungenkrebs - ALK - Herztransplantation - Herzinsuffizienz - Lorlatinib

Keywords

lung cancer - ALK - heart transplant - heart failure - lorlatinib

Publication History

Received: 07 May 2025

Accepted after revision: 29 September 2025

Article published online:
11 November 2025

• Literatur

• 1 Stenman C, Wallinder A, Holmberg E. et al. Malignancies After Heart Transplantation. Transpl Int 2024; 37: 12109
• 2 Heil KM, Helmschrott M, Darche FF. et al. Risk Factors, Treatment and Prognosis of Patients with Lung Cancer after Heart Transplantation. Life (Basel) 2021; 11: 1344
• 3 Goeckenjan G, Sitter H, Thomas M. et al. Prevention, diagnosis, therapy, and follow-up of lung cancer. Interdisciplinary guideline of the German Respiratory Society and the German Cancer Society – abridged version. Pneumologie 2011; 65: e51-e75
• 4 Chevallier M, Borgeaud M, Addeo A. et al. Oncogenic driver mutations in non-small cell lung cancer: Past, present and future. World J Clin Oncol 2021; 12: 217-237
• 5 Solomon BJ, Liu G, Felip E. et al. Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study. J Clin Oncol 2024; 42: 3400-3409
• 6 Ou SH, Tong WP, Azada M. et al. Heart rate decrease during crizotinib treatment and potential correlation to clinical response. Cancer 2013; 119: 1969-1975
• 7 Soria JC, Tan DSW, Chiari R. et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet 2017; 389: 917-929
• 8 Yang JC, Liu G, Lu S. et al. Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial. J Thorac Oncol 2023; 18: 1743-1755
• 9 Yuan D, Zhu F, Zuo R. et al. High incidence and reversible bradycardia events following alectinib initiation. Thorac Cancer 2023; 14: 479-488
• 10 Poei D, Ali S, Ye S. et al. ALK inhibitors in cancer: mechanisms of resistance and therapeutic management strategies. Cancer Drug Resist 2024; 7: 20
• 11 Higgins R, Ramaiyan K, Dasgupta T. et al. Hyponatraemia and hyperkalaemia are more frequent in renal transplant recipients treated with tacrolimus than with cyclosporin. Further evidence for differences between cyclosporin and tacrolimus nephrotoxicities. Nephrol Dial Transplant 2004; 19: 444-450
• 12 Hoorn EJ, Walsh SB, McCormick JA. et al. The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension. Nat Med 2011; 17: 1304-1309
• 13 Luo Y, Zhang Z, Guo X. et al. Comparative safety of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced anaplastic lymphoma kinase-mutated non-small cell lung cancer: Systematic review and network meta-analysis. Lung Cancer 2023; 184: 107319
• 14 Francisco LM, Salinas VH, Brown KE. et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 2009; 206: 3015-3029
• 15 Maggiore U, Palmisano A, Buti S. et al. Chemotherapy, targeted therapy and immunotherapy: Which drugs can be safely used in the solid organ transplant recipients?. Transplant International 2021; 34: 2442-2458
• 16 Fisher J, Zeitouni N, Fan W. et al. Immune checkpoint inhibitor therapy in solid organ transplant recipients: A patient-centered systematic review. J Am Acad Dermatol 2020; 82: 1490-1500
• 17 Nielsen DL, Juhl CB, Nielsen OH. et al. Immune Checkpoint Inhibitor-Induced Cardiotoxicity: A Systematic Review and Meta-Analysis. JAMA Oncol 2024; 10: 1390-1399
• 18 Laenens D, Yu Y, Santens B. et al. Incidence of Cardiovascular Events in Patients Treated With Immune Checkpoint Inhibitors. J Clin Oncol 2022; 40: 3430-3438